Advertisement
Skip to Content
Morningstar

Exact Sciences Corp EXAS Stock Quote

Morningstar Rating
| Rating as of

NASDAQ: EXAS

Last close prices updated as of Jun 09, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 87.81
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Investment Style Mid Growth
  • Day Range 87.73  –  90.87
  • Year Range 29.27  –  91.19
  • Market Cap 15.8475 Bil
  • Volume / Avg 2.0 Mil /  1.9 Mil
  • Price / Sales 7.08
  • Price / Book 5.18
  • Forward Div Yield —
  • Trailing Div Yield —

Morningstar‘s Stock Analysis EXAS

Valuation
Currency in —
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Exact Sciences Earnings: Cologuard Strength Improves Projected Timeline to Free Cash Flow

Julie Utterback Senior Equity Analyst

Analyst Note

| Julie Utterback |

Exact Sciences delivered strong first-quarter results on better-than-anticipated Cologuard expansion that allowed management to increase its 2023 sales outlook and accelerate its timeline to reaching positive free cash flow in 2023, up from 2024. Exact's positive sales growth and profit trends inform our positive moat trend, although we do not think Exact has dug an economic moat quite yet. Based on these positive trends, we have tinkered with our near-term assumptions slightly, but we do not anticipate changing our $64 fair value estimate materially. Shares remain about fairly valued, too.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics EXAS

More

Company Profile EXAS

Business Description

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.

Contact
5505 Endeavor Lane
Madison, WI, 53719
Sector Healthcare
Industry Diagnostics & Research
Employees 6,400

Related Articles EXAS

US Videos

3 Stocks, 1 Potentially Explosive Growth Theme

Plus, our take on Nvidia stock and our market outlook for June.
David Sekera
Stock Strategist

2 Undervalued Medtech Stocks: Opportunities in Liquid Biopsy

Liquid biopsies could usher in a paradigm shift in cancer detection and grow exponentially.
David Sekera
Stock Analyst Update

Exact Sciences Earnings: Cologuard Strength Improves Projected Timeline to Free Cash Flow

Julie Utterback
Stock Analyst Update

Exact Sciences Provides Underwhelming 2023 Outlook

Shares are fairly valued.
Julie Utterback
Fund Spy

A Bold Fund Blindsided by a Biotech Blowup

Invesco Global Opportunities took a big hit when its Nektar stock lost that sweet taste.
Gregg Wolper
Commentary

ARK Innovation Has Likely Been a Disappointment for Most Investors

Following a frenzy of inflows, investors are fleeing for the exits amid the fund's underperformance this year.
Katherine Lynch
Our Picks

3 Stocks to Forget

These no-moat stocks have lost more than 20% this year yet remain overpriced.
Susan Dziubinski
Stock Strategist Industry Reports

A New Frontier in Cancer Screening and Treatment

If liquid biopsy lives up to its potential, a paradigm shift in cancer detection is possible.
Julie Utterback

Related News EXAS

More

Competitors & Peers EXAS

More on EXAS’s Competitors & Peers

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of EXAS’s competitive advantage.

Exact Sciences Corp

XNAS: EXAS

Illumina Inc

XNAS: ILMN

Myriad Genetics Inc

XNAS: MYGN

Guardant Health Inc

XNAS: GH
Price
87.81200.5323.3032.86
Currency
USDUSDUSDUSD
Change
−$2.84 (3.13%) −$2.19 (1.08%) +$0.04 (0.17%) +$0.27 (0.83%)
Market Cap
15.85 Bil31.70 Bil1.90 Bil3.85 Bil
Industry
Diagnostics & Research Diagnostics & Research Diagnostics & Research Diagnostics & Research
Sector
Healthcare
Healthcare
Healthcare
Healthcare

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Exact Sciences Corp Stock

No. EXAS does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

EXAS’s market cap is 15.85 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

EXAS’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

EXAS’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare EXAS’s historical performance against its industry peers and the overall market.